For years, doctors prescribed separate inhalers: a corticosteroid (anti‑inflammatory) and a bronchodilator (airway opener). Now, combination drugs like budesonide‑formoterol are taking over. The India respiratory drugs market research shows that combination drugs are the fastest‑growing drug class, with a CAGR above 8%. Why? Because one inhaler does both, improving adherence and outcomes.

What's the evidence? The GINA (Global Initiative for Asthma) guidelines now recommend SMART therapy — using a single combination inhaler for both maintenance and rescue. That means fewer inhalers to carry, less confusion. The India respiratory drugs market trends highlight that retail pharmacies are the dominant distribution channel, but online pharmacies are growing fast — patients can order inhalers discreetly and get home delivery.

But there's a catch: combination inhalers are more expensive than generic ICS alone. And not all patients need them — mild asthma may be controlled with low‑dose ICS. Overprescribing is a risk.

The bottom line: if you have moderate‑to‑severe asthma or COPD, ask your doctor about a combination inhaler. It could simplify your life and keep you out of hospital.